Publication: Experiencia de uso en el tratamiento del cáncer renal en un hospital terciario
Loading...
Official URL
Full text at PDC
Publication Date
2015-02
Advisors (or tutors)
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
Citations
Exportar
Abstract
El Carcinoma de Células Renales (CCR) representa el 3% de todos los tumores sólidos y el 2% de las muertes por cáncer. El pronóstico de enfermedad en etapa temprana es excelente pero, sin embargo, la mayoría de los pacientes tienen enfermedad avanzada en el diagnóstico y un 30% presenta enfermedad metastásica. El 4% de los tumores renales se asocian a síndromes hereditarios.
El CCR puede permanecer clínicamente silente durante gran parte de su evolución dando síntomas en fases avanzadas de la enfermedad. Dichos síntomas son: hematuria, dolor abdominal y masa abdominal palpable.
Se han desarrollado nuevos fármacos capaces de bloquear distintas vías de señalización molecular: inhibidores de la tirosina kinasa (sunitinib, sorafenib, pazopanib y axitinib); inhibidores de la enzima mTOR (temsirolimus y everolimus) y el anticuerpo monoclonal bevacizumab.
En este trabajo hemos estudiado como la terapia intravenosa ha sido desplazada por la oral en los pacientes con cáncer renal.
Renal Cell Carcinoma (RCC) represents a 3% of all solid tumors and a 2% of cancer deaths. The prognosis of early stage disease is excellent, however most patients have advanced disease at diagnosis and 30% have metastatic disease. A 4% of renal tumors are associated with inherited syndromes. The RCC can remain clinically silent during its evolution appearing symptoms in advanced stages of the disease. These symptoms are: hematuria, abdominal pain and palpable abdominal mass. New drugs have been developed with the capacity to block different molecular signaling pathways: kinase inhibitors (sunitinib, sorafenib, pazopanib and axitinib) tyrosine; mTOR enzyme inhibitors (temsirolimus and everolimus) and the monoclonal antibody bevacizumab. During this project we have studied how intravenous therapy has been substituted by oral in patients with renal cancer.
Renal Cell Carcinoma (RCC) represents a 3% of all solid tumors and a 2% of cancer deaths. The prognosis of early stage disease is excellent, however most patients have advanced disease at diagnosis and 30% have metastatic disease. A 4% of renal tumors are associated with inherited syndromes. The RCC can remain clinically silent during its evolution appearing symptoms in advanced stages of the disease. These symptoms are: hematuria, abdominal pain and palpable abdominal mass. New drugs have been developed with the capacity to block different molecular signaling pathways: kinase inhibitors (sunitinib, sorafenib, pazopanib and axitinib) tyrosine; mTOR enzyme inhibitors (temsirolimus and everolimus) and the monoclonal antibody bevacizumab. During this project we have studied how intravenous therapy has been substituted by oral in patients with renal cancer.